Press Releases and News
Pluristyx to Support Development of Kiadis’ K-NK Cell COVID-19 Therapy Funded by $9.5 Million From the Advanced Regenerative Manufacturing Institute’s BioFabUSA Program
November 12, 2020
Accelerated Biosciences’ Immune-Privileged Human Trophoblast Stem Cells (hTSCs) Offer Breakthrough Opportunities in Cancer-Targeting Therapeutics and Regenerative Medicine Treatments | Business Wire
May 11, 2021
AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications
June 16, 2020
